Immuno-oncology developer Agenus' Q1 revenue rises, posts profit

Agenus

11/05/2026 13:53

Overview

US immuno-oncology developer's Q1 revenue grew yr/yr, driven by BOT+BAL program

Company reported positive net income for Q1, compared to loss in prior yr

Agenus closed Zydus collaboration, strengthening capital and securing U.S. manufacturing capacity

Outlook

Company continues to align operating expenses with approximately $50 mln in annualized spending

Agenus plans to advance regulatory submissions for BOT+BAL in the US and EU

Company expects continued expansion of BOT+BAL access through regulatory-authorized pathways in select countries

Result Drivers

EARLY ACCESS PROGRAMS - Pre-commercial product revenue in Q1 came from BOT+BAL provided to hospitals and physicians under regulatory-authorized early access pathways, including France's AAC framework and paid named-patient programs in other countries

ZYDUS COLLABORATION - Closing of Zydus collaboration in January delivered upfront capital, contingent payments, and dedicated U.S. manufacturing capacity, supporting clinical and commercial readiness

PHYSICIAN ENGAGEMENT - Expanded physician requests and engagement for BOT+BAL through regulatory-authorized access pathways in multiple regions

Company press release: ID:nBw3q6DCba

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$33.7 mln
$129.50 mln (1 Analyst)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Agenus Inc is $15.50, about 305.8% above its May 8 closing price of $3.82

The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 2 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)